These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
320 related articles for article (PubMed ID: 37441388)
21. Understanding the CD8 T-cell response in natural HIV control. Boppana S; Goepfert P F1000Res; 2018; 7():. PubMed ID: 30026916 [TBL] [Abstract][Full Text] [Related]
22. Progress in achieving long-term HIV remission. Pino M; Paiardini M; Marconi VC Curr Opin HIV AIDS; 2018 Sep; 13(5):435-445. PubMed ID: 29889662 [TBL] [Abstract][Full Text] [Related]
23. Two Distinct Mechanisms Leading to Loss of Virological Control in the Rare Group of Antiretroviral Therapy-Naive, Transiently Aviremic Children Living with HIV. Vieira VA; Adland E; Grayson NE; Csala A; Richards F; Dacon C; Athavale R; Tsai MH; D'Souza R; Muenchhoff M; Bonsall D; Jooste P; Goulder PJR J Virol; 2022 Jan; 96(2):e0153521. PubMed ID: 34757843 [TBL] [Abstract][Full Text] [Related]
24. Interferon Alpha Enhances NK Cell Function and the Suppressive Capacity of HIV-Specific CD8 Kwaa AKR; Talana CAG; Blankson JN J Virol; 2019 Feb; 93(3):. PubMed ID: 30404799 [TBL] [Abstract][Full Text] [Related]
25. γδ T cells: an immunotherapeutic approach for HIV cure strategies. Garrido C; Clohosey ML; Whitworth CP; Hudgens M; Margolis DM; Soriano-Sarabia N JCI Insight; 2018 Jun; 3(12):. PubMed ID: 29925697 [TBL] [Abstract][Full Text] [Related]
26. Perspectives on inducing efficient immune control of HIV-1 replication--a new goal for HIV therapeutics? Bucy RP; Kilby JM AIDS; 2001 Feb; 15 Suppl 2():S36-42. PubMed ID: 11424975 [TBL] [Abstract][Full Text] [Related]
27. Combined Effects of HLA-B*57/5801 Elite Suppressor CD8+ T Cells and NK Cells on HIV-1 Replication. May ME; Pohlmeyer CW; Kwaa AK; Mankowski MC; Bailey JR; Blankson JN Front Cell Infect Microbiol; 2020; 10():113. PubMed ID: 32266164 [TBL] [Abstract][Full Text] [Related]
28. Harnessing Natural Killer Cell Innate and Adaptive Traits in HIV Infection. Alrubayyi A; Ogbe A; Moreno Cubero E; Peppa D Front Cell Infect Microbiol; 2020; 10():395. PubMed ID: 32850493 [TBL] [Abstract][Full Text] [Related]
29. The B-Cell Follicle in HIV Infection: Barrier to a Cure. Bronnimann MP; Skinner PJ; Connick E Front Immunol; 2018; 9():20. PubMed ID: 29422894 [TBL] [Abstract][Full Text] [Related]
30. Functional Signatures of Human CD4 and CD8 T Cell Responses to Mycobacterium tuberculosis. Prezzemolo T; Guggino G; La Manna MP; Di Liberto D; Dieli F; Caccamo N Front Immunol; 2014; 5():180. PubMed ID: 24795723 [TBL] [Abstract][Full Text] [Related]
31. Immune interventions in HIV infection. Carcelain G; Autran B Immunol Rev; 2013 Jul; 254(1):355-71. PubMed ID: 23772631 [TBL] [Abstract][Full Text] [Related]
32. Nonhuman Primate Testing of the Impact of Different Regulatory T Cell Depletion Strategies on Reactivation and Clearance of Latent Simian Immunodeficiency Virus. Sivanandham R; Kleinman AJ; Sette P; Brocca-Cofano E; Kilapandal Venkatraman SM; Policicchio BB; He T; Xu C; Swarthout J; Wang Z; Pandrea I; Apetrei C J Virol; 2020 Sep; 94(19):. PubMed ID: 32669326 [TBL] [Abstract][Full Text] [Related]
33. New challenges in therapeutic vaccines against HIV infection. Leal L; Lucero C; Gatell JM; Gallart T; Plana M; García F Expert Rev Vaccines; 2017 Jun; 16(6):587-600. PubMed ID: 28431490 [TBL] [Abstract][Full Text] [Related]
34. CD8(+)T-cell-mediated control of HIV-1 and SIV infection. Freel SA; Saunders KO; Tomaras GD Immunol Res; 2011 Apr; 49(1-3):135-46. PubMed ID: 21170741 [TBL] [Abstract][Full Text] [Related]
35. Challenges and Opportunities for T-Cell-Mediated Strategies to Eliminate HIV Reservoirs. Brockman MA; Jones RB; Brumme ZL Front Immunol; 2015; 6():506. PubMed ID: 26483795 [TBL] [Abstract][Full Text] [Related]
36. Differentiation and Function of Follicular CD8 T Cells During Human Immunodeficiency Virus Infection. Xiao M; Chen X; He R; Ye L Front Immunol; 2018; 9():1095. PubMed ID: 29872434 [TBL] [Abstract][Full Text] [Related]
37. Redirection of Cord Blood T Cells and Natural Killer Cells for Elimination of Autologous HIV-1-Infected Target Cells Using Bispecific DART® Molecules. Pollara J; Edwards RW; Jha S; Lam CK; Liu L; Diedrich G; Nordstrom JL; Huffman T; Pickeral JA; Denny TN; Permar SR; Ferrari G Front Immunol; 2020; 11():713. PubMed ID: 32373131 [TBL] [Abstract][Full Text] [Related]
38. Modulation of HIV reservoirs by host HLA: bridging the gap between vaccine and cure. Brumme ZL; Chopera DR; Brockman MA Curr Opin Virol; 2012 Oct; 2(5):599-605. PubMed ID: 22939190 [TBL] [Abstract][Full Text] [Related]
39. Recent Advances in Lentiviral Vaccines for HIV-1 Infection. Norton TD; Miller EA Front Immunol; 2016; 7():243. PubMed ID: 27446074 [TBL] [Abstract][Full Text] [Related]
40. Measuring the Success of HIV-1 Cure Strategies. Thomas J; Ruggiero A; Paxton WA; Pollakis G Front Cell Infect Microbiol; 2020; 10():134. PubMed ID: 32318356 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]